SubsidieMeestersAI-powered platform for autologous iPSC manufacturing
The project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration.
Projectdetails
Introduction
Induced pluripotent stem cells (iPSCs) can be differentiated into any cell type of the body and transplanted without rejection. The potential of iPSCs to cure health problems including degenerative diseases, cancer, cancer therapy-associated diseases, and defective tissues is unprecedented in history. However, the current methodologies prohibit standardized production of a person's own (autologous) iPSCs; hence rejection is taking place and the therapeutic promise is not fulfilled.
Project Objectives
Our consortium seeks to develop a new technology that will enable the mass production of personalized iPSCs for:
- Autologous adoptive cancer immunotherapies
- Hematopoietic stem cell transplantation
- Tissue regeneration
Innovative Technology
The consortium will, for the first time, create an artificial intelligence (AI) guided microfluidic device that:
- Standardizes the GMP production of autologous iPSCs
- Produces them quickly and at a fraction of the current cost
Moreover, it will conduct cutting-edge single-cell genomics and bioinformatics research of iPSCs to identify clones of the highest quality. This research will lead to the development of a database that will serve as the basis for AI software to select clones that meet clinical standards.
Consortium Expertise
The consortium comprises experts in:
- Microfluidics engineering
- Process automation for cell therapies
- Stem cell molecular biology and bioinformatics
- GMP production
- AI modeling
The participating companies, startups, and universities are among the leading entities in Europe. They will promote the positions of female and early career participants from both developed and developing European countries.
Goals and Implementation
The consortium aims to reach the TRL3 prototype stage and has created a concrete exploitation plan to develop the technology further for implementation in cancer therapy and regenerative medicine.
Conclusion
Altogether, we propose to create revolutionary technology for low-cost, fast, and standardized automated mass production of autologous iPSCs. This holds the potential to enable numerous new therapies and make them accessible to the public.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 3.999.225 |
| Totale projectbegroting | € 3.999.225 |
Tijdlijn
| Startdatum | 1-9-2022 |
| Einddatum | 31-8-2026 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- MIDA BIOTECH BVpenvoerder
- DEEPPATH MONOPROSOPI I.K.E
- UNIVERSITEIT LEIDEN
- MIRCOD
- BIT BIO DISCOVERY GMBH
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process controlThe SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors. | EIC Pathfinder | € 1.364.281 | 2022 | Details |
NOn-VIral gene modified STEM cell therapyThis project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application. | EIC Pathfinder | € 3.644.418 | 2022 | Details |
Targeting cancer with mutanome based stem cell vaccineMUTAVAC aims to enhance IPVAC, an innovative cancer immunotherapy leveraging iPSC technology, by uncovering its mechanisms, improving immunogenicity, and paving the way for personalized cancer vaccines. | EIC Pathfinder | € 1.782.000 | 2022 | Details |
Hyper-targeting CAR NK cells from induced pluripotent stem cells for novel off-the-shelf anti-tumor therapiesThe HyperTargIPS-NK project aims to develop a scalable, off-the-shelf NK cell therapy using iPS cells to target and treat lethal cancers like pancreatic cancer, glioblastoma, and AML. | EIC Pathfinder | € 3.798.713 | 2023 | Details |
Automated online monitoring & control to improve processes and decision making in cell and gene therapy manufacturingThe project aims to develop an automated, self-contained bioreactor with continuous monitoring of critical process parameters to enhance scalability and quality in cell and gene therapy manufacturing. | EIC Pathfinder | € 3.617.783 | 2022 | Details |
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process control
The SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors.
NOn-VIral gene modified STEM cell therapy
This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.
Targeting cancer with mutanome based stem cell vaccine
MUTAVAC aims to enhance IPVAC, an innovative cancer immunotherapy leveraging iPSC technology, by uncovering its mechanisms, improving immunogenicity, and paving the way for personalized cancer vaccines.
Hyper-targeting CAR NK cells from induced pluripotent stem cells for novel off-the-shelf anti-tumor therapies
The HyperTargIPS-NK project aims to develop a scalable, off-the-shelf NK cell therapy using iPS cells to target and treat lethal cancers like pancreatic cancer, glioblastoma, and AML.
Automated online monitoring & control to improve processes and decision making in cell and gene therapy manufacturing
The project aims to develop an automated, self-contained bioreactor with continuous monitoring of critical process parameters to enhance scalability and quality in cell and gene therapy manufacturing.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Scaling up iPSC Expansion and Differentiation using Recombinant BioemulsionsThe project aims to develop scalable, regulatory-compliant bioemulsions using engineered protein nanosheets for efficient iPSC culture and differentiation, enhancing cell manufacturing and biotech market growth. | ERC Proof of... | € 150.000 | 2025 | Details |
Rapid Interventional Stem cells Platform 2.0 (RISP)Dit project richt zich op de ontwikkeling en validatie van een modulair, op afstand bestuurbaar platform voor de veilige productie en kwaliteitscontrole van (stam)celproducten, met als doel wereldwijde distributie. | Mkb-innovati... | € 180.430 | 2018 | Details |
Dissecting the molecular regulation of hematopoietic stem cell emergence using pluripotent stem cells to improve ex vivo therapiesThis project aims to develop methods for generating and expanding hematopoietic stem cells from patient-specific induced pluripotent stem cells to overcome transplantation barriers and enhance therapies. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Paving the way for off-the-shelf adoptive Treg therapy using epigenetic forward programmingThis project aims to develop a novel method for creating off-the-shelf regulatory T cells from human induced pluripotent stem cells through epigenetic editing for therapeutic use. | ERC Proof of... | € 150.000 | 2025 | Details |
Efficient, safe, and cost-efficient RNA delivery vehicles for hard-to-transfect pre-clinical and therapeutic cells.The project aims to develop inteRNAlizers, a novel non-viral RNA delivery system for efficient and safe gene modification in hIPSCs and other cells, enhancing gene delivery for research and therapies. | ERC Proof of... | € 150.000 | 2023 | Details |
Scaling up iPSC Expansion and Differentiation using Recombinant Bioemulsions
The project aims to develop scalable, regulatory-compliant bioemulsions using engineered protein nanosheets for efficient iPSC culture and differentiation, enhancing cell manufacturing and biotech market growth.
Rapid Interventional Stem cells Platform 2.0 (RISP)
Dit project richt zich op de ontwikkeling en validatie van een modulair, op afstand bestuurbaar platform voor de veilige productie en kwaliteitscontrole van (stam)celproducten, met als doel wereldwijde distributie.
Dissecting the molecular regulation of hematopoietic stem cell emergence using pluripotent stem cells to improve ex vivo therapies
This project aims to develop methods for generating and expanding hematopoietic stem cells from patient-specific induced pluripotent stem cells to overcome transplantation barriers and enhance therapies.
Paving the way for off-the-shelf adoptive Treg therapy using epigenetic forward programming
This project aims to develop a novel method for creating off-the-shelf regulatory T cells from human induced pluripotent stem cells through epigenetic editing for therapeutic use.
Efficient, safe, and cost-efficient RNA delivery vehicles for hard-to-transfect pre-clinical and therapeutic cells.
The project aims to develop inteRNAlizers, a novel non-viral RNA delivery system for efficient and safe gene modification in hIPSCs and other cells, enhancing gene delivery for research and therapies.